希少バイオマーカー検体の収集と安定化市場：製品タイプ、収集タイプ、用途、最終用途別-2025-2030年世界予測

希少バイオマーカー検体の収集と安定化市場は、2023年に299億4,000万米ドルと評価され、2024年には322億1,000万米ドルに達すると予測され、CAGR 7.54％で成長し、2030年には498億3,000万米ドルになると予測されています。

希少バイオマーカー検体収集・安定化市場は、極微量に存在する明確な生物学的マーカーの収集、保存、分析に焦点を当てた専門ヘルスケア分野を包含しています。これらのバイオマーカーは、疾患の早期診断、個別化医療、長期的な健康モニタリングに不可欠です。この市場の必要性は、精密医療に対する需要の高まりから生じており、供給源から分析に至るまで生物学的完全性を維持できる高感度技術が必要とされています。アプリケーションは腫瘍学、出生前検査、神経学、感染症診断に及び、エンドユーザーには臨床検査機関、研究・学術機関、バイオ製薬会社などが含まれます。市場成長の原動力は、診断技術の進歩、バイオマーカー研究への資金提供の増加、慢性疾患の有病率の上昇です。例えば、個別化医療を支援する政府のイニシアチブは、市場の可能性を大きく押し上げます。市場拡大の機会としては、検体の収集と安定化のワークフローを合理化する自動化やデジタルソリューションの開発が挙げられます。しかし、厳しい規制の枠組み、高い運用コスト、経時的な検体の劣化を管理する技術的限界などの課題も残っています。また、最先端のバイオマーカー技術に精通した熟練した専門家が不足していることも制限要因となっています。革新的な技術としては、携帯可能で使い勝手の良い採取装置の開発や、コールドチェーン物流に大きく依存することなく検体の保存期間を延長する新しい安定化方法などが考えられます。市場は本質的に競争的で細分化されており、老舗企業も新興企業も存在するのが特徴です。技術の進歩や規制状況のダイナミックな性質は、チャンスでもあり脅威でもあります。初期段階のイノベーションのための学術研究機関との提携など、協力的な試みに投資することは、優位に立つための有望な戦略です。企業は、適応性の高い技術に焦点を当て、市場情勢の変化を予測するために厳密なマーケット・インテリジェンスを実施し、新たなニーズに対応できる体制を整え、特定されたギャップを活用することをお勧めします。

市場力学：急速に進化する希少バイオマーカー検体の収集と安定化市場の主要市場インサイトを公開

希少バイオマーカー検体の収集と安定化市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 非侵襲的な疾患治療への嗜好の高まり
  • 個別化医療への需要の高まり
  • 循環バイオマーカーの役割を明らかにするための調査件数の増加
• 市場抑制要因
  • 業界における厳しい規制
• 市場機会
  • リキッドバイオプシーアッセイなどの新規アッセイの革新
  • 市場開拓のための共同イニシアティブ
• 市場の課題
  • 限られた償還シナリオ
  • 特性解析の複雑さと非効率的な分離プロトコル

ポーターのファイブフォース：希少バイオマーカー検体の収集と安定化市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：希少バイオマーカー検体の収集と安定化市場における外部からの影響の把握

外部マクロ環境要因は、希少バイオマーカー検体の収集と安定化市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析希少バイオマーカー検体の収集と安定化市場における競合情勢の把握

希少バイオマーカー検体の収集と安定化市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス希少バイオマーカー検体の収集と安定化市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、希少バイオマーカー検体の収集と安定化市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨希少バイオマーカー検体の収集と安定化市場における成功への道筋を描く

希少バイオマーカー検体の収集と安定化市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 非侵襲的な病気治療の好感度が高まっている
    • 個別化医療の需要増加
    • 循環バイオマーカーの役割を描写する調査の増加
  • 抑制要因
    • 業界の厳しい規制
  • 機会
    • 液体生検アッセイなどの新しいアッセイの革新
    • 市場開発のための共同イニシアチブ
  • 課題
    • 限定的な償還シナリオ
    • 特性評価の複雑さと非効率的な分離プロトコル
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 希少バイオマーカー検体の収集と安定化市場：製品タイプ別

• 循環細胞遊離DNA
• 循環腫瘍細胞
• エクソソームまたは細胞外小胞

第7章 希少バイオマーカー検体の収集と安定化市場コレクションタイプ別

• 採血管および採血システム
• 分離キットと試薬

第8章 希少バイオマーカー検体の収集と安定化市場：用途別

• 心血管疾患
• NIPT
• 腫瘍学
• 薬理ゲノム学
• 人口スクリーニング
• トランスクリプトミクス
• 移植拒絶反応

第9章 希少バイオマーカー検体の収集と安定化市場：最終用途別

• 病院
• 周産期クリニック
• 医師ラボ
• 民間または商業ラボ
• 公衆衛生研究所
• 調査機関

第10章 南北アメリカの希少バイオマーカー検体の収集と安定化市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の希少バイオマーカー検体の収集と安定化市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの希少バイオマーカー検体の収集と安定化市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ABL, Inc.
• ACM Global Laboratories
• Almac Group
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BioAgilytix Labs, LLC
• bioMerieux, Inc.
• Charles River Laboratories International, Inc.
• IQVIA Inc.
• Labcorp Drug Development
• NorthEast BioAnalytical Laboratories LLC
• PerkinElmer Inc.
• SGS Societe Generale de Surveillance SA
• Svar Life Science AB
• Synexa Life Sciences BV

LIST OF FIGURES

• FIGURE 1. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET RESEARCH PROCESS
• FIGURE 2. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET DYNAMICS
• TABLE 7. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY CIRCULATING CELL FREE DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY EXOSOMES OR EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY BLOOD COLLECTION TUBES & SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY ISOLATION KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY NIPT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY TRANSCRIPTOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY TRANSPLANT REJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PERINATAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PHYSICIAN LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRIVATE OR COMMERCIAL LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. CHINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CHINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. CHINA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ITALY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 139. ITALY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. ITALY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. POLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 155. POLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. POLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 158. QATAR RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 159. QATAR RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. QATAR RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY COLLECTION TYPE, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 197. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 198. RARE BIOMARKERS SPECIMEN COLLECTION & STABILIZATION MARKET, FPNV POSITIONING MATRIX, 2023

The Rare Biomarkers Specimen Collection & Stabilization Market was valued at USD 29.94 billion in 2023, expected to reach USD 32.21 billion in 2024, and is projected to grow at a CAGR of 7.54%, to USD 49.83 billion by 2030.

The rare biomarkers specimen collection and stabilization market encompasses a specialized healthcare sector focused on collecting, preserving, and analyzing distinct biological markers that are present in minuscule quantities. These biomarkers are critical for early disease diagnosis, personalized medicine, and longitudinal health monitoring. The necessity of this market arises from the increasing demand for precision medicine, necessitating highly sensitive technologies capable of preserving biological integrity from source to analysis. Applications span oncology, prenatal testing, neurology, and infectious disease diagnostics, with end-users including clinical laboratories, research and academic institutions, and biopharmaceutical companies. Market growth is driven by advances in diagnostic technologies, increased funding for biomarker research, and the rising prevalence of chronic diseases. For instance, government initiatives supporting personalized medicine boost market potential significantly. Opportunities for expansion include developing automation and digital solutions that streamline specimen collection and stabilization workflows. However, challenges persist, including stringent regulatory frameworks, high operational costs, and technological limitations in managing specimen degradation over time. Another limiting factor is the shortage of skilled professionals adept in cutting-edge biomarker technologies. Innovations could include developing portable and user-friendly collection devices and novel stabilization methods that extend the shelf-life of specimens without heavy reliance on cold-chain logistics. The market is inherently competitive and fragmented, characterized by the presence of well-established companies and startups alike. The dynamic nature of technological advancements and regulatory landscapes can be both an opportunity and a threat. Investing in collaborative endeavors, such as partnerships with academic and research institutions for early-stage innovations, presents a promising strategy to stay ahead. Businesses are advised to focus on adaptive technologies and conduct rigorous market intelligence to anticipate shifts in the market landscape, ensuring they are poised to address emerging needs and capitalizing on identified gaps.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Biomarkers Specimen Collection & Stabilization Market

The Rare Biomarkers Specimen Collection & Stabilization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising preference of a non-invasive mode of disease treatment
  • Increasing demand for personalized medicine
  • Growth in number of research studies to depict the role of circulating biomarkers
• Market Restraints
  • Stringent regulations in the industry
• Market Opportunities
  • Innovation of novel assays such as liquid biopsy assays
  • Collaborative initiatives for market developments
• Market Challenges
  • Limited reimbursement scenario
  • Complexities in characterization and ineffective separation protocols

Porter's Five Forces: A Strategic Tool for Navigating the Rare Biomarkers Specimen Collection & Stabilization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Biomarkers Specimen Collection & Stabilization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Biomarkers Specimen Collection & Stabilization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Biomarkers Specimen Collection & Stabilization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Biomarkers Specimen Collection & Stabilization Market

A detailed market share analysis in the Rare Biomarkers Specimen Collection & Stabilization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Biomarkers Specimen Collection & Stabilization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Biomarkers Specimen Collection & Stabilization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rare Biomarkers Specimen Collection & Stabilization Market

A strategic analysis of the Rare Biomarkers Specimen Collection & Stabilization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rare Biomarkers Specimen Collection & Stabilization Market, highlighting leading vendors and their innovative profiles. These include ABL, Inc., ACM Global Laboratories, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux, Inc., Charles River Laboratories International, Inc., IQVIA Inc., Labcorp Drug Development, NorthEast BioAnalytical Laboratories LLC, PerkinElmer Inc., SGS Societe Generale de Surveillance SA, Svar Life Science AB, and Synexa Life Sciences BV.

Market Segmentation & Coverage

This research report categorizes the Rare Biomarkers Specimen Collection & Stabilization Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Circulating Cell Free DNA, Circulating Tumor Cells, and Exosomes or Extracellular Vesicles.
• Based on Collection Type, market is studied across Blood Collection Tubes & Systems and Isolation Kits & Reagents.
• Based on Application, market is studied across Cardiovascular Diseases, NIPT, Oncology, Pharmacogenomics, Population Screening, Transcriptomics, and Transplant Rejection.
• Based on End Use, market is studied across Hospitals, Perinatal Clinics, Physician Labs, Private or Commercial Labs, Public Health Labs, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising preference of a non-invasive mode of disease treatment
    • 5.1.1.2. Increasing demand for personalized medicine
    • 5.1.1.3. Growth in number of research studies to depict the role of circulating biomarkers
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations in the industry
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovation of novel assays such as liquid biopsy assays
    • 5.1.3.2. Collaborative initiatives for market developments
  • 5.1.4. Challenges
    • 5.1.4.1. Limited reimbursement scenario
    • 5.1.4.2. Complexities in characterization and ineffective separation protocols
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Rare Biomarkers Specimen Collection & Stabilization Market, by Product Type

• 6.1. Introduction
• 6.2. Circulating Cell Free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Exosomes or Extracellular Vesicles

7. Rare Biomarkers Specimen Collection & Stabilization Market, by Collection Type

• 7.1. Introduction
• 7.2. Blood Collection Tubes & Systems
• 7.3. Isolation Kits & Reagents

8. Rare Biomarkers Specimen Collection & Stabilization Market, by Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases
• 8.3. NIPT
• 8.4. Oncology
• 8.5. Pharmacogenomics
• 8.6. Population Screening
• 8.7. Transcriptomics
• 8.8. Transplant Rejection

9. Rare Biomarkers Specimen Collection & Stabilization Market, by End Use

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Perinatal Clinics
• 9.4. Physician Labs
• 9.5. Private or Commercial Labs
• 9.6. Public Health Labs
• 9.7. Research Institutes

10. Americas Rare Biomarkers Specimen Collection & Stabilization Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Rare Biomarkers Specimen Collection & Stabilization Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Rare Biomarkers Specimen Collection & Stabilization Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ABL, Inc.
• 2. ACM Global Laboratories
• 3. Almac Group
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. BioAgilytix Labs, LLC
• 7. bioMerieux, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. IQVIA Inc.
• 10. Labcorp Drug Development
• 11. NorthEast BioAnalytical Laboratories LLC
• 12. PerkinElmer Inc.
• 13. SGS Societe Generale de Surveillance SA
• 14. Svar Life Science AB
• 15. Synexa Life Sciences BV